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Edited by Christian GriesingerAbstract The combined use of a rapid virtual screen of a small
fragment library together with a single point enzyme assay has
been used for the discovery of novel PNP inhibitors. The avail-
ability of readily soakable crystals of bovine PNP has allowed
the approach to be experimentally validated by determining the
crystal structure of one of the inhibitor-PNP complexes. Com-
parison of the experimentally determined binding mode with that
predicted by the virtual screening shows them to be similar. This
represents a starting point for the growth of the ligand into a
higher aﬃnity inhibitor.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Purine nucleoside phosphorylase (PNP) (EC 2.4.2.1) cata-
lyzes the cleavage of the glycosidic bond in purine ribo- and
deoxyribonucleosides, in the presence of inorganic orthophos-
phate (Pi) as a second substrate, to generate the corresponding
purine base and (deoxy)ribose1-phosphate.
It has been widely suggested that human PNP should be
considered a primary target for chemotherapeutic intervention
[1] and many studies of potential applications of PNP inhibi-
tors as therapeutic agents have been undertaken. Examples
include their use in the selective suppression of cellular immu-
nity, in the treatment of malignant lymphoproliferative disor-
ders and to counter autoimmunity [2].
Current approaches to ﬁnding new leads for therapeutic tar-
gets are increasingly based on three-dimensional information
about receptors. As increasing numbers of 3D structures for
pharmaceutically relevant targets become available, eﬃcient
techniques for their exploitation are gaining ground over ran-
dom experimental screening [3]. As a consequence, novel lead
discovery by computer-based virtual screening has become
part of the standard toolbox of techniques used in the early
stages of the structure-based drug development process. Data-
base searching or docking approaches that select small molec-
ular weight compounds that are structurally or energetically*Corresponding author. Fax: +55 16 33739881.
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romolecule have been reasonably successful in the past few
years [4].
More recently, interest has grown in a new approach for lead
generation that involves screening libraries of compounds that
are signiﬁcantly smaller and functionally simpler than drug
molecules [5]. This approach is often referred to as ‘frag-
ment-based’ discovery, and presents several advantages over
conventional screening. These include a more eﬃcient sam-
pling of chemical space using fewer compounds and a more ra-
pid hit-to lead optimization phase. However, fragment-based
discovery also presents signiﬁcant challenges, largely due to
the fact that fragments typically exhibit only poor binding
aﬃnities (of the order of 100 lM–mM) and are therefore diﬃ-
cult to detect using bioassay-based screening methods [6].
Here, we describe the screening of a small library of low
molecular weight compounds using the three-dimensional
structure of calf spleen PNP as a model for its human homo-
logue. Despite the relatively small size of both the library
and its component compounds, a novel base-binding site
ligand was readily identiﬁed and its ternary structure in com-
plex with PNP and sulfate is reported here.2. Materials and methods
2.1. BovPNP virtual screening
Using the calf spleen PNP structure (bovPNP) in the form of its
complex with 9-deazainosine and phosphate (PDB code 1A9P) [7] a
virtual screen was performed in order to identify compounds that
may be potential binders. For this purpose the coordinates corre-
sponding to the 9-deazainosine and phosphate ligands were removed
from the structure ﬁle the key residues in the trimeric bovPNP active
site were identiﬁed and assigned for use in the virtual screening. These
included all residues which interact directly with one of the ligands:
G32, S33, H64, R84, H82, Y88, A116, A117, F200, E201, M219,
S220, T242, N245 and H257. The maximum molecular weight of the
compounds used in the search was 280 Da, which are part of a proprie-
tary ASTEX database including 30000 compounds. The program
Gold [8] was used for virtual screening employing the GOLD virtual
screening parameters and goldscore as a scoring function. The best
scored solutions were inspected manually and 19 compounds that
interacted favourably with key residues in the active site were selected
for activity assays.
2.2. PNP activity assays using bovPNP
Inosine phosphorolysis by PNP was assayed by the coupled xanthine
oxidase method of Kalckar [9]. This method consists of the measure-
ment of the hypoxanthine released during phosphorolysis of inosine
or deoxyinosine indirectly by monitoring the uric acid produced by
xanthine oxidase on its oxidation. The reaction mixture (ﬁnal volumeblished by Elsevier B.V. All rights reserved.
Table 1
Full data collection and reﬁnement statistics
Data collection parameters
Space group P213
Cell dimensions (A˚) a=b=c=93.44
Detector ADSC Quantum 4
X-ray source PX14.2 SRS Daresbury
Wavelength (A˚) 0.980
Resolution range (A˚) 54.23–2.10 (2.21–2.10)
Redundancy 4.9 (3.0)
Rmeas (%) 8.7 (24.7)
Rsym (%) 7.8 (21.0)
Completeness (%) 97.3 (84.2)
Total reﬂections 145465
Unique reﬂections 15761
I/rI 7.5 (3.2)
Reﬁnement parameters
R (%) 16.77
Rfree (%) 21.75
Ramachandran plot
Most favoured region (%) 93.2
No. of residues in disallowed regions 1
Overall B-factor (protein) 27.1
Mean B-factor (ligand) 19.32
No. of protein atoms (one monomer) 2090
No. of water molecules 140
No. of ligand atoms 18
r.m.s. bond lengths (A˚) 0.016
r.m.s. bond angles () 1.492
Table 2
Results for the activity assays against bovPNP with the compounds
from virtual screening
Compound % of inhibition
VS1 97.38
VS2 98.92
VS3 0
VS4 0
VS5 2.29
VS6 0
VS7 1.22
VS8 0
VS9 0
VS10 2.04
VS11 0
VS12 23.84
VS13 14.13
VS14 1.68
VS15 3.66
VS16 45.53
VS17 79.8
H.M. Pereira et al. / FEBS Letters 581 (2007) 5082–5086 50831 ml) contained 50 mM potassium phosphate buﬀer pH 7.0, 100 ll of
DMSO (in which the potential inhibitors identiﬁed during virtual
screening were dissolved at a concentration of 100 lM), 100 lM ino-
sine and 0.02 U of xanthine oxidase. The reaction was started by addi-
tion of 550 ng of bovPNP to the reaction mixture and the OD293 was
monitored for 2 min. The IC50 for the compound (VS1 – IUPAC
name; 4-imino-7-methyl-1,2,3,4-tetrahydropyrazolo [1,5-a] [1,3,5] tria-
zin-2-one) was determined using the same method in the presence of
VS1 at concentrations of 0,5 lM, 1 lM, 2,5 lM, 5 lM and 10 lM,
using the same procedure described above.
2.3. Puriﬁcation, crystallization and soaking of bovPNP
The puriﬁcation protocol used was that given by Mao et al. [7] with
minor modiﬁcations. Calf spleen PNP in ammonium sulfate (SIGMA)
was dissolved in 50 mM Tris/HCl pH 7.0, 200 mM NaCl plus 5 mM b-
mercaptoethanol concentrated to about 6 mg/ml, and applied to a
Sephacryl S200 26/60 column, pre-equilibrated with the same buﬀer.
The fractions containing bovPNP were pooled, dialysed against 100
volumes of 10 mM HEPES pH 7.0 plus 5 mM b-mercapthoethanol
and concentrated to 30 mg/ml (based on e0:1%280 ¼ 0:964). The dialysed
bovPNP was incubated with 1% octyl b-D-glucopyranoside prior to
crystallization according to the method of Mao et al. [7] which con-
sisted of 31–35% PEG 400, 100 mM Tris or HEPES buﬀer pH 7.8–
8.2, 100 mM MgCl2 using 30 mg/ml bovPNP. The drops consisted of
2 ll of bovPNP plus 2 ll of crystallization solution and were incubated
at 18 C.
The soaking parameters for bovPNP crystals were modiﬁed from
those of Mao et al. [7] and consisted of 50% PEG 400, 10% DMSO
(in which the compound was dissolved at a concentration of 5 mM)
and 100 mM HEPES or Tris/HCl buﬀer (at the pH of crystal growth).
This solution is also a cryoprotectant allowing for the rapid freezing of
the crystals directly from the soaking solutions.
2.4. X-ray data collection
X-ray diﬀraction data were collected at 100 K to a resolution of
2.1 A˚ from a bovPNP crystal after soaking with the compound VS1.
Measurements were made on Station PX14.2 of the SRS (Dares-
bury-UK) using k = 0.980 A˚, over 1 increments in u for a total rota-
tion of 45. The data were indexed and integrated using the program
MOSFLM [10] and scaled using the program SCALA from the
CCP4 suite [11].
2.5. Structure solution and reﬁnement
The structure of the complex bovPNP-VS1 was solved by molecular
replacement using the programMOLREP [12], employing bovine PNP
coordinates (PDB ID 1a9r) as the search model. The molecular
replacement (MR) solution was essentially a rigid body reﬁnement as
a consequence of the fact that the crystals were isomorphous and con-
tained one monomer per asymmetric unit. The reﬁnement was carried
out using both CNX [13] and REFMAC [14] and the model building
performed with Quanta (Accelrys) and COOT [15], using ra-weighted
2Fo–Fc and Fo–Fc electron density maps. A total of 140 water mole-
cules were included using both COOT and ARP-wARP [16] and the
VS1 and a sulfate ion were added using the X-ligand [17] module of
Quanta. The full statistics of data collection and reﬁnement are shown
in Table 1.
In all cases the behaviour of Rfree was used as the principal criterion
for validating the reﬁnement protocol and the stereochemical quality
of the model was evaluated with Procheck [18]. The coordinates and
structure factors have been deposited with the PDB under the follow-
ing code: 2QP2.3. Results and discussion
3.1. Virtual Screening and activity assays
100 compounds presenting the highest docking scores were
subjected to visual inspection and 19 were selected on the basis
of their drug-like properties and potential favourable interac-
tions for a rapid one-point activity assay, the results of which
are given in Table 2. In this context ‘‘drug-like’ takes into
account Lipinski’s ‘‘rule-of-ﬁve’’ [19] and its modiﬁed version,the ‘‘rule-of-three’’ for small fragment-like compounds [20]
The majority of these compounds are not purines or purine-like
but often contain one or more aromatic rings. VS1 however is
the only purine-like compound within this set, diﬀering from a
standard purine due to its 2-oxy substituent, a nitrogen at posi-
tion 5, an imine group on the 6 position and the presence of an
8-methyl group (using purine nomenclature). The assay dis-
criminated false hits from true ligands and served as a ﬁlter
for choosing compounds for subsequent soaking experiments.
In this screening assay a total of six compounds presented some
level of inhibitory activity against calf spleen PNP but only two
(VS1 and VS2) inhibited above 95% of the control. The IC50
value for the VS1 compound was 18.9 ± 5.9 lM, demonstrating
that the combined use of virtual screening and a single point as-
say was able to identify low molecular weight compounds with
relatively high aﬃnity for the target.
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Despite many soaking attempts with several of the active
compounds given in Table 2, up until now only one complex
has been successfully obtained, that of calf spleen PNP and
VS1. The overall structure of this complex is similar to those
with hypoxanthine [21] and a multisubstrate inhibitor [22], as
well as several others described by Mao et al. [7]. Some resi-
dues showed no electron density in the ﬁnal structure. These
include two residues at the N-terminus, residues 59-62 involved
in the phosphate binding site and residues 250–260 which in
some structures form the a-helix that interacts with H257 of
the ribose binding site. A magnesium ion participates in the
crystal packing.
3.3. The active site of the ternary complex
The active site of the ternary complex contains one sulfate
ion (occupying the phosphate binding site), one molecule of
VS1, and two water molecules. Residues E201 and N243 form
three hydrogen bonds to VS1 while F200, A117 and T242 con-
tribute to hydrophobic interactions (Fig. 1)
As can be seen in Fig. 2, the binding mode of the inhibitor in
the experimentally determined structure is very similar to that
predicted by virtual screening. In order to accommodate the
methyl group at position 8 on VS1, small distortions occur
at the base binding site (BBS). For example the distance be-
tween Oc1 of T242 and the terminal oxygens of E201 (a mea-
surement which describes the overall dimension of the BBS)
increases by 0.51 and 0.97 A˚, respectively, when compared
with the ternary complex between bovine PNP, hypoxanthineFig. 1. Electron density map 2FoFc at 1r for theand sulfate (1A9R). More important is an in-plane rotation of
the ligand about the 5 position of the purine base as can be
seen in Fig. 3. This allows the simultaneous formation of
two hydrogen bonds with the side chain oxygens of E201;
one with the 2-oxo substituent and the second with the nitro-
gen at the 1 position. A further consequence of this rotation
is that the imino group at position 6 of VS1, which substitutes
the 6-oxo of hypoxanthine, moves further from the N243 side-
chain to a distance of 3.31 A˚. The hydrogen bond observed in
the complex with hypoxanthine, at a distance of 3.08 A˚, is
therefore weakened. In both structures the strong hydrogen
bond between the Od1 of N243 and the 7-position is main-
tained. As a consequence the two structures have the same to-
tal number of hydrogen bonds (three) despite their distinct
arrangements.
In the complex described here, the H-bond between T242
and N243 is signiﬁcantly weakened if not broken altogether,
as the separation between the two side chains increases from
3.02 A˚ in the hypoxanthine complex to 3.54 A˚. This occurs
as a consequence of small structural diﬀerences which are
necessary in order to accommodate the methyl group at the
8 position of VS1, which is absent in hypoxanthine. Neverthe-
less the distance between this methyl and the Oc1 of T242 is
only 2.44 A˚ which is surprisingly short. Indeed purines with
8-amino substituents often form hydrogen bonds to this side-
chain. Clearly the formation of the three strong hydrogen
bonds described above is suﬃcient to energetically compensate
this close contact thus permitting relatively tight binding.
Within this context it is noteworthy that the hydrogen bondactive site of bovPNP in complex with VS1.
Fig. 2. The base binding site of bovine PNP. Comparison of the crystal structure of the complex (yellow) and that predicted by VS (green). In (A) the
VS was performed assuming E201 to be non-protonated and the side chain of N243 to have the same orientation as that observed in 1A9P. In (B)
E201 was treated as protonated and the side chain of N243 was ﬂipped with respect to its orientation in 1A9P. In the former case the docked
compound is orientated diﬀerently to that observed in the crystal structure while in the latter the superposition is markedly improved.
Fig. 3. Superposition of the base binding site for bovine PNP in complex with hypoxanthine (white) and VS1 (yellow).
H.M. Pereira et al. / FEBS Letters 581 (2007) 5082–5086 5085formed by N243 and the 7-position in VS1 is shorter than that
observed with hypoxanthine (2.55 compared with 2.88 A˚) as a
consequence of the base rotation.
The binding of VS1 to the PNP active site induces a series of
conformational changes to the protein. Residues 262–278,
when compared with the 1A9R structure, possess an RMSD
of 2.05 A˚ due to a deviation in the course of the polypeptide
chain which leads to an increased disorder to residues 250–
261 (which are absent in the structure described here). A large
movement is also observed to the loop centered on residue S33,
which is part of the phosphate binding site, despite the factthat the sulfate observed in both structures occupies eﬀectively
an identical position. However, it is often diﬃcult to correlate
the precise details of the diﬀerences observed in loop confor-
mation with the structure of a given ligand, due to the known
inherent plasticity of the PNP active site.
In conclusion, we have demonstrated the eﬃciency of the
combined use of a rapid virtual screen of a small fragment
library together with a single point enzyme assay for the rapid
discovery of novel PNP inhibitors. The availability of a
soakable system for crystallographic studies has allowed us
to validate the results by the determination of the crystal
5086 H.M. Pereira et al. / FEBS Letters 581 (2007) 5082–5086structure of the complex and subsequently compare it with
that predicted by the original docking. This represents a start-
ing point for the growth of the original fragment into a higher
aﬃnity inhibitor and is complementary to traditional purine
based crystallographic screening [23].
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